August 2024

Contents

Conference reports

• AIDS 2024: Ten early reports

• Five days on two days off: Biktarvy in pilot FOTO study

• Subcutaneous formulation of long-acting CAB/RPV discontinued

• First data on third-generation integrase inhibitor from ViiV

• Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study

Antiretrovirals

• BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024

mpox

• WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study